Although the precise role of IL-33 in EAE/MS remains to be clarified, our findings agree with a previous report, where levels of IL-33 in the CNS correlate with EAE severity, being also in line with treatments, such as vitamin D or anti-CD52, in which the reduction of IL-33 expression levels in spinal cord tissue is associated with an improvement of both clinical symptoms and neuroinflammation, observed in EAE-treated mice [29,30,31]. This evidence concerns the gene CD52 and myeloid sarcoma.